Guangzhou Eighth People’s Hospital | China
Author Profile
ORCID ID
🌟Linghua Li, Ph.D., M.S., B.S. 🌍
Head Director, Infectious Disease Center
Guangzhou Eighth People’s Hospital, Guangzhou Medical University
👩⚕️Biography
Dr. Linghua Li is a distinguished physician and researcher specializing in HIV/AIDS, infectious diseases, and oncology. With over 25 years of clinical experience, she has made significant contributions to understanding and managing infectious diseases, particularly fungal infections and HIV-related complications.
Dr. Li began her academic journey at the Medical School of Peking University, earning a B.S. in Clinical Medicine in 1997. She then pursued advanced studies at Sun Yat-sen University, completing an M.S. in Internal Medicine in 2008 and a Ph.D. in Infectious Diseases in 2011. She further enriched her expertise through visiting scholar positions at UNC-Chapel Hill (2012) and Duke University (2014), focusing on infectious diseases.
As the Head Director of the Infectious Disease Center at Guangzhou Eighth People’s Hospital, Dr. Li oversees clinical trials, patient care, and research initiatives for people living with HIV and at-risk populations. She has been principal investigator (PI) or co-investigator (Co-I) on more than 20 domestic and international research programs. Notable projects include:
- National Natural Science Foundation of China (Grant No. 81301480): Investigating the mechanism and function of Phospholipase B in the growth and pathogenicity of P. marneffei.
- Guangdong Natural Science Foundation (Grant No. 10151006002000000): Exploring the role of Phospholipase B in P. marneffei invasion of macrophages in AIDS patients.
- NIH Fogarty Program: Examining host factors in severe opportunistic complications of AIDS, with a focus on developing targeted prophylactic strategies.
In recent years, Dr. Li has been a Co-PI on groundbreaking HIV PrEP Phase IV clinical trials in Guangzhou, including:
- ChiCTR2100048981 and NCT04754139: These studies focus on scaling PrEP access for key populations in China. The trial successfully enrolled 1,007 participants by 2023, with 950 already on PrEP, marking it as the largest trial of its kind in China.
Dr. Li’s work emphasizes translational medicine, data-driven public health strategies, and the implementation of novel interventions like PrEP to curb HIV transmission. Her expertise in site coordination, implementation, data collection, and analysis has been pivotal to these efforts.
🧬Key Areas of Expertise
🔬 HIV Prevention and Treatment
🌿 Opportunistic Infections
📊 Clinical Trials and Data Analysis
🧑⚕️ Internal and Infectious Diseases
📚Academic Background
- B.S., Clinical Medicine, Medical School of Peking University (1997)
- M.S., Internal Medicine, Sun Yat-sen University (2008)
- Ph.D., Infectious Diseases, Sun Yat-sen University (2011)
- Visiting Scholar, UNC-Chapel Hill (2012)
- Visiting Scholar, Duke University (2014)
🔬Research Impact
🌟 Over 20 funded research projects
📄 Numerous publications in infectious disease and public health journals
📚 Active contributor to advancing HIV prevention strategies in China
Dr. Linghua Li remains a leader in the fight against infectious diseases, with a career dedicated to improving global health outcomes. 🌏✨
✨ Conclusion
Dr. Linghua Li’s career exemplifies dedication to advancing the prevention, treatment, and understanding of infectious diseases, particularly HIV/AIDS and associated complications. Through her leadership, innovative research, and clinical expertise, she has significantly impacted global health, especially in developing effective interventions like PrEP for key populations in China. Her contributions to translational medicine and public health continue to pave the way for breakthroughs in managing infectious diseases and improving the lives of those affected worldwide. 🌟🌍